Raised serum lactate dehydrogenase (LDH) levels in patients with various types of cancer have been reported on several occasions (Hill and Levi, 1954; Bierman, Hill, Emory, Reinhardt, and Samuels, 1955; Albaum, Antopol, Kabakow, Slapikoff, Blinick, Sussman, and Ginzburg, 1961) . Gold (1961) reported raised levels in 28 out of 34 (82%0b) proven cases of bronchial carcinoma. It was thought that if this finding was substantiated serum LDH would make a useful supplementary test in the diagnosis of bronchial cancer.
METHOD AND CASE MATERIAL
The method used was a colorimetric one (King and Wootton, 1964) developed from the method of Wr6blewski and LaDue (1955 Tables I and II. The raised levels were mainly in the range 175-300 i.u., but values from 500 to 2,100 i.u. were obtained in patients whose livers were markedly enlarge-d by metastases. Zimmerman and Weinstein (1956) found eight out of 13 (62%). However, neither of these authors states whether metastases were present in his patients. In the present series, in which only 10 198 out of 39 (26%) had raised values at the first estimation, nine out of the 10 had definite evidence of metastases. Likewise, in four patients who had slowly growing, but nevertheless progressive, primary lesions but in whom there was no evidence of secondary deposits, the serum LDH value did not rise to an abnormal level in the course of six months.
A reasonable explanation of the discrepancy between the results in this series and those of Gold (1961) is that there was a much higher proportion of cases with metastases in his group of patients.
The results show that in practice the serum LDH is of little use in the diagnosis of bronchial carcinoma since in only a small proportion of cases is the level raised in the absence of secondary deposits. The main significance of a raised value is a prognostic one, since the majority of patients with abnormal levels had died within six months. 
